Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MBS ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares MBS ETF trades at $89.99 (market cap $35.58B). The key difference: iShares MBS ETF is far larger — about 12.4× Dyne Therapeutics Inc. Common Stock's market cap, and iShares MBS ETF is more actively traded (3,918,815 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MBS ETF for 97 Days on average.
| DYN | MBB | |
|---|---|---|
Market Cap | $2.86B | $35.58B |
Volume | 3,341,579 | 3,918,815 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $96.91 |
52-Week Low | $14.60 | $89.09 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MBB trades at $90.00 with minimal daily movement (+0.19%). Technical indicators signal bearish momentum with RSI at overbought levels and moving averages trending downward. Recent news highlights significant short interest growth (98.3% increase in September 2026) and concerns about intermediate duration risk amid potential rate hikes. The ETF faces pressure from rising rates while maintaining consistent dividend distributions.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. While institutional buying provides some support, the combination of high short interest and duration risk creates headwinds. Investors should weigh the steady income against potential price depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
